JP2025537239A - Ｋｒａｓ＿ｇ１２ｖ変異抗原特異的ｔｃｒ、並びに、斯かるｔｃｒ及びｃｄ８を共発現する再指向化ｃｄ４ ｔ細胞 - Google Patents

Ｋｒａｓ＿ｇ１２ｖ変異抗原特異的ｔｃｒ、並びに、斯かるｔｃｒ及びｃｄ８を共発現する再指向化ｃｄ４ ｔ細胞

Info

Publication number
JP2025537239A
JP2025537239A JP2025526492A JP2025526492A JP2025537239A JP 2025537239 A JP2025537239 A JP 2025537239A JP 2025526492 A JP2025526492 A JP 2025526492A JP 2025526492 A JP2025526492 A JP 2025526492A JP 2025537239 A JP2025537239 A JP 2025537239A
Authority
JP
Japan
Prior art keywords
amino acid
seq
chain
cdr3 amino
changed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025526492A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025537239A5 (enExample
Inventor
ソンミン ペン
ドゥオ アン
シャン ジョン
Original Assignee
ネオワイズ バイオテクノロジー カンパニー，リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネオワイズ バイオテクノロジー カンパニー，リミテッド filed Critical ネオワイズ バイオテクノロジー カンパニー，リミテッド
Publication of JP2025537239A publication Critical patent/JP2025537239A/ja
Publication of JP2025537239A5 publication Critical patent/JP2025537239A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
JP2025526492A 2022-11-04 2023-02-24 Ｋｒａｓ＿ｇ１２ｖ変異抗原特異的ｔｃｒ、並びに、斯かるｔｃｒ及びｃｄ８を共発現する再指向化ｃｄ４ ｔ細胞 Pending JP2025537239A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202211379445.6A CN115960204B (zh) 2022-11-04 2022-11-04 Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
CN202211379445.6 2022-11-04
PCT/CN2023/078124 WO2024093056A1 (zh) 2022-11-04 2023-02-24 Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞

Publications (2)

Publication Number Publication Date
JP2025537239A true JP2025537239A (ja) 2025-11-14
JP2025537239A5 JP2025537239A5 (enExample) 2026-02-27

Family

ID=87362539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025526492A Pending JP2025537239A (ja) 2022-11-04 2023-02-24 Ｋｒａｓ＿ｇ１２ｖ変異抗原特異的ｔｃｒ、並びに、斯かるｔｃｒ及びｃｄ８を共発現する再指向化ｃｄ４ ｔ細胞

Country Status (6)

Country Link
US (1) US20260176324A1 (enExample)
EP (1) EP4613762A1 (enExample)
JP (1) JP2025537239A (enExample)
CN (2) CN115960204B (enExample)
AU (1) AU2023371349A1 (enExample)
WO (1) WO2024093056A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118852403A (zh) * 2023-04-26 2024-10-29 北京鼎成肽源生物技术有限公司 靶向kras突变的tcr分子和细胞及其应用
CN118852452A (zh) * 2023-04-28 2024-10-29 北京鼎成肽源生物技术有限公司 靶向kras g12突变的tcr分子和细胞及其应用
CN118909132A (zh) * 2023-05-06 2024-11-08 北京鼎成肽源生物技术有限公司 靶向kras g12v突变的tcr分子和细胞及其应用
WO2025056681A1 (en) * 2023-09-15 2025-03-20 Medigene Immunotherapies Gmbh T-CELL RECEPTOR AGAINST mKRAS7-16 G12V AND G12C
CN120157754A (zh) * 2023-12-14 2025-06-17 新景智源生物科技(苏州)有限公司 Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
CN120518771A (zh) * 2024-02-20 2025-08-22 上海信谱生物医药科技有限公司 一种识别kras突变的t细胞受体及其编码序列

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020005765A (es) * 2017-12-04 2020-09-25 Us Health Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado.
CN112646024B (zh) * 2019-10-10 2023-03-24 香雪生命科学技术（广东）有限公司 一种识别kras突变的t细胞受体及其编码序列
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
CN112300269B (zh) * 2020-09-29 2022-12-09 中国科学院微生物研究所 Kras突变特异性t细胞受体筛选及抗肿瘤用途

Also Published As

Publication number Publication date
CN117430689A (zh) 2024-01-23
CN115960204B (zh) 2023-08-25
AU2023371349A1 (en) 2025-05-22
WO2024093056A1 (zh) 2024-05-10
US20260176324A1 (en) 2026-06-25
CN115960204A (zh) 2023-04-14
EP4613762A1 (en) 2025-09-10

Similar Documents

Publication Publication Date Title
EP4613762A1 (en) Kras_g12v mutant antigen-specific tcr and redirected cd4 t cell co-expressing same and cd8
JP7037577B2 (ja) 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用
KR20210139472A (ko) 조작된 iPSC 및 면역 효과기 세포에서의 CD3 재구성
CN111263808B (zh) 一种靶向HPK1的gRNA和一种编辑HPK1基因的方法
KR20180021137A (ko) 키메라 항원 수용체 (car), 조성물 및 이의 사용 방법
US12398191B2 (en) BRAF-specific TCRs and uses thereof
JP2020535796A (ja) ｓｔｒｅｐタグ特異的キメラ受容体およびその使用
JP2021534752A5 (enExample)
JP2022525099A (ja) 高アビディティｗｔ１ｔ細胞受容体とその使用
EP4682162A1 (en) Tcr specifically recognizing prame antigen, and co-expressing same with cd8 for redirecting cd4 t cells
KR20230008144A (ko) Cd19를 표적화하는 키메라 항원 수용체 및 그의 용도
KR20220050176A (ko) Wt-1에 특이적인 t-세포 면역요법
KR20210102231A (ko) 메소텔린에 특이적인 t 세포 수용체 및 면역요법에서의 그의 용도
US20250177531A1 (en) Binding proteins specific for ras neoantigens and uses thereof
KR20220057596A (ko) 동종이계 세포 조성물 및 사용 방법
WO2019140278A1 (en) Immunotherapy targeting core binding factor antigens
KR20230010597A (ko) 트랜스포존 시스템 및 이의 용도
WO2025124489A1 (zh) Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
HK40101993A (en) Kras_g12v mutant antigen specific tcr and its co-expression with cd8 to redirect cd4 t cells
HK40086029A (en) Kras_g12v mutant antigen specific tcr and its co-expression with cd8 to redirect cd4 t cells
HK40086029B (en) Kras_g12v mutant antigen specific tcr and its co-expression with cd8 to redirect cd4 t cells
HK40099427A (en) Tcr specific recognizing prame antigen, and co-expression thereof with cd8 to redirect cd4 t cells
HK40099427B (en) Tcr specific recognizing prame antigen, and co-expression thereof with cd8 to redirect cd4 t cells
CN116731155B (zh) 人乳头瘤病毒特异性t细胞受体、表达其的细胞和其用途
CN118165098A (zh) 特异性识别egfr l858r突变抗原的tcr及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260217